| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIGINAL ARTICLE |
1 Oral Pathology, School of Dentistry, Federal University of Pelotas/UFP, Pelotas, Rio Grande do Sol, Brazil, CEP 96015
2 Oral Pathology, School of Dentistry, University of São Paulo/USP, Säo Paulo, Brazil, CEP 1509-900
3 Head and Neck Surgery and Otorhinolaryngology Department, Cancer Hospital AC Camargo, São Paulo, Brazil, 01509010
4 Pathology Department, Cancer Hospital A. C. Camargo, São Paulo, Brazil
Correspondence to:
Dr V C de Araújo
Faculdade de Odontologia da Universidade de São Paulo/USP, São Paulo, Avenida Prof. Lineu de Azevedo Prestes, 2227, Cidade Universitária, São Paulo, SP, Brasil, CEP: 01509-900; vcaraujo{at}usp.br
Background: Salivary duct carcinoma (SDC) is considered to be a distinct malignancy of the major salivary glands, because of its highly aggressive behaviour, and the high rate of recurrence, metastasis, and disease related death.
Aims: To investigate expression of the proteins involved in the retinoblastoma (pRb) and p53 pathways, which control cell cycle progression at the G1/S checkpoint, and also expression of the c-erbB-2 oncoprotein in SDCs.
Methods: Using a streptavidin–biotin method, five cases of SDC were evaluated immunohistochemically for the presence of cyclin D1, CDK4 (cyclin dependent kinase 4), p16 (CDK2A), pRb (retinoblastoma protein), E2F-1, p53, mdm2 (murine double minute 2), bcl-2, and the c-erbB-2 oncoprotein to determine whether there was a correlation between the expression of these proteins and patient outcome.
Results: All of the cases showed deregulation of the pRb and p53 pathways. Of the five patients analysed, only the patient with longterm survival (10 years) was not positive for c-erbB-2 expression.
Conclusions: c-erbB-2 overexpression was associated with a poor prognosis. Aggressive behaviour, recurrence, and metastatic potential do not appear to be related to cell cycle deregulation, but seem to be associated with the c-erbB-2 oncoprotein, which is involved in matrix degradation and proteolitic activity, in addition to increases in vessel permeability, endothelial cell growth, proliferation, migration, and differentiation. There was a correlation between c-erbB-2 oncoprotein expression and aggressive behaviour in SDCs.
Keywords: cell cycle; retinoblastoma protein; c-erbB-2; salivary duct carcinoma; salivary gland tumour
Abbreviations: CDK, cyclin dependent kinase; mdm2, murine double minute 2; pRB, retinoblastoma protein; SGT, salivary gland tumour
This article has been cited by other articles:
|
|
 |
|
  M. Agulnik, E. W.E. Cohen, R. B. Cohen, E. X. Chen, E. E. Vokes, S. J. Hotte, E. Winquist, S. Laurie, D. N. Hayes, J. E. Dancey, et al. Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands J. Clin. Oncol., September 1, 2007; 25(25): 3978 - 3984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Pannellini, M. Spadaro, E. Di Carlo, E. Ambrosino, M. Iezzi, A. Amici, P. L. Lollini, G. Forni, F. Cavallo, and P. Musiani Timely DNA Vaccine Combined with Systemic IL-12 Prevents Parotid Carcinomas before a Dominant-Negative p53 Makes Their Growth Independent of HER-2/neu Expression. J. Immunol., June 15, 2006; 176(12): 7695 - 7703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Laurie and L. Licitra Systemic Therapy in the Palliative Management of Advanced Salivary Gland Cancers J. Clin. Oncol., June 10, 2006; 24(17): 2673 - 2678. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |
